Research progress of platelets in liver cirrhosis

doi:10.3760/cma.j.issn.1007-1245.2023.12.003

Abstract

Abstract:

Platelets, the main effector cells in hemostasis, undergo dynamic changes in their structure and function and are involved in complex pathophysiological processes through granule release, associated signaling receptors, and platelet aggregation and activation. Significant thrombocytopenia is present in patients with cirrhosis, and increasing evidences suggest that platelets play important roles in processes such as immune inflammation, host defense, angiogenesis, tissue repair, regeneration, etc. The potential role of platelets in cirrhosis is reviewed in the hope of improving the survival quality of patients with cirrhosis.

Key words:

Platelets, Cirrhosis, MiRNA, Progress

摘要：

血小板是止血的主要效应细胞，其结构和功能是动态变化的，通过颗粒释放、相关表面受体、血小板的聚集和活化等参与复杂的病理生理过程。肝硬化患者中存在明显的血小板减少，且越来越多的证据表明，血小板在免疫炎症、宿主防御、血管生成、组织修复和再生等过程中发挥重要作用。本文对血小板在肝硬化中潜在的作用予以综述，以期提高肝硬化患者生存质量。

关键词:

血小板, 肝硬化, miRNA, 进展

Zhou Zhaonian, Zheng Weiqiang.

Research progress of platelets in liver cirrhosis [J]. International Medicine and Health Guidance News, 2023, 29(12): 1640-1643.

周兆年郑伟强.

血小板在肝硬化中的研究进展 [J]. 国际医药卫生导报, 2023, 29(12): 1640-1643.

References

[1] Violi F, Basili S, Raparelli V, et al. Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?[J]. J Hepatol, 2011,55(6):1415-1427. DOI: 10.1016/j.jhep.2011.06.008.
[2] Ferroni P, Mammarella A, Martini F, et al. Increased soluble P-selectin levels in hepatitis C virus-related chronic hepatitis: correlation with viral load[J]. J Investig Med, 2001,49(5):407-12. DOI: 10.2310/6650.2001. 33785.
[3] 陈月,于月新.维生素K对肝硬化患者凝血功能、血小板的影响[J].国际医药卫生导报,2020,26(22):3473-3475.DOI:10.3760/cma.j.issn.1007-1245.2020.22.033.
[4] Vieira-de-Abreu A, Campbell RA, Weyrich AS, et al. Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum[J]. Semin Immunopathol, 2012,34(1):5-30. DOI: 10.1007/s00281- 011-0286-4.
[5] Iannacone M, Sitia G, Isogawa M, et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage[J]. Nat Med, 2005,11(11):1167-1169. DOI: 10.1038/nm1317.
[6] Pereboom IT, Lisman T, Porte RJ. Platelets in liver transplantation: friend or foe? [J] Liver Transpl, 2008,14(7):923-931. DOI: 10.1002/lt.21510.
[7] Jacob G, Bishara B, Lee SS, et al. Cardiovascular responses to serotonin in experimental liver disease[J]. Hepatology, 1991,14(6):1235-1242.
[8] He C, Zhai M, Shu B, et al. 5-HT and Intraplatelet 5-HT: a potential upstream regulator of YAP in liver regeneration[J]. Exp Mol Med, 2019,51(10):1-2. DOI: 10.1038/s12276-019-0324-1.
[9] Nagao Y, Akahoshi T, Kamori M, et al. Liver regeneration is promoted by increasing serotonin content in rat liver with secondary biliary cirrhosis[J]. Hepatol Res, 2011,41(8):784-94. DOI: 10.1111/j.1872-034X.2011.00828.x.
[10] Semela D, Das A, Langer D, et al. Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function[J]. Gastroenterology, 2008,135(2):671-679. DOI: 10.1053/j.gastro.2008. 04.010.
[11] Siegerstetter V, Huber M, Ochs A, et al. Platelet aggregation and platelet-derived growth factor inhibition for prevention of insufficiency of the transjugular intrahepatic portosystemic shunt: a randomized study comparing trapidil plus ticlopidine with heparin treatment[J]. Hepatology, 1999,29(1):33-38. DOI: 10.1002/hep.510290139.
[12] Mejias M, Garcia-Pras E, Tiani C, et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats[J]. Hepatology, 2009,49(4):1245-1256. DOI: 10.1002/hep.22758.
[13] Jiang S, Ai Y, Ni L, et al. Platelet-derived TGF-β1 is related to portal vein thrombosis in cirrhosis by promoting hypercoagulability and endothelial dysfunction[J]. Front Cardiovasc Med, 2022,9:938397. DOI: 10.3389/fcvm. 2022.938397.
[14] Malehmir M, Pfister D, Gallage S, et al. Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer[J]. Nat Med, 2019,25(4):641-655. DOI: 10.1038/s41591-019-0379-5.
[15] Xu M, Li J, Neves MAD, et al. GPIbα is required for platelet-mediated hepatic thrombopoietin generation[J]. Blood, 2018,132(6):622-634. DOI: 10.1182/blood-2017- 12-820779.
[16] Zhang H, Zhang S, Zhang J, et al. Improvement of human platelet aggregation post-splenectomy with paraesophagogastric devascularization in chronic hepatitis B patients with cirrhotic hypersplenism[J]. Platelets, 2020,31(8):1019-1027. DOI: 10.1080/09537104. 2019.1704715.
[17] Kajihara M, Kato S, Okazaki Y, et al. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis[J]. Hepatology, 2003,37(6):1267-1276. DOI: 10.1053/jhep. 2003.50209.
[18] Byrne MF, Kerrigan SW, Corcoran PA, et al. Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation[J]. Gastroenterology, 2003,124(7):1846-1854. DOI: 10.1016/s0016-5085(03)00397-4.
[19] Peter K, Schwarz M, Ylänne J, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors[J]. Blood, 1998,92(9):3240-3249. DOI: 10.1182/blood.V92.9.3240.
[20] Selzner N, Selzner M, Odermatt B, et al. ICAM-1 triggers liver regeneration through leukocyte recruitment and Kupffer cell-dependent release of TNF-alpha/IL-6 in mice[J]. Gastroenterology, 2003,124(3):692-700. DOI: 10.1053/gast.2003.50098.
[21] Geerts AM, Cheung KJ, Van Vlierberghe H, et al. Decreased leukocyte recruitment in the mesenteric microcirculation of rats with cirrhosis is partially restored by treatment with peginterferon: an in vivo study[J]. J Hepatol, 2007,46(5):804-815. DOI: 10.1016/j.jhep.2006.11.014.
[22] Haselmayer P, Grosse-Hovest L, von Landenberg P, et al. TREM-1 ligand expression on platelets enhances neutrophil activation[J]. Blood, 2007,110(3):1029-1035. DOI: 10.1182/blood-2007-01-069195.
[23] Ichou L, Carbonell N, Rautou PE, et al. Ascitic fluid TREM-1 for the diagnosis of spontaneous bacterial peritonitis[J]. Gut, 2016,65(3):536-538. DOI: 10.1136/gutjnl-2015-310160.
[24] Nguyen-Lefebvre AT, Ajith A, Portik-Dobos V, et al. The innate immune receptor TREM-1 promotes liver injury and fibrosis[J]. J Clin Invest, 2018,128(11):4870-4883. DOI: 10.1172/JCI98156.
[25] Stravitz RT, Bowling R, Bradford RL, et al. Role of procoagulant microparticles in mediating complications and outcome of acute liver injury/acute liver failure[J]. Hepatology, 2013,58(1):304-313. DOI: 10.1002/hep.26307.
[26] Rautou PE, Vion AC, Valla D, et al. Circulating platelet derived microparticles are not increased in patients with cirrhosis[J]. J Hepatol, 2013,59(4):912. DOI: 10.1016/j.jhep.2013.05.048.
[27] Ye D, Zhang T, Lou G, et al. Role of miR-223 in the pathophysiology of liver diseases[J]. Exp Mol Med, 2018,50(9):1-12. DOI: 10.1038/s12276-018-0153-7.
[28] Kobus K, Kopycinska J, Kozlowska-Wiechowska A, et al. Angiogenesis within the duodenum of patients with cirrhosis is modulated by mechanosensitive Kruppel-like factor 2 and microRNA-126[J]. Liver Int, 2012,32(8):1222-1232. DOI: 10.1111/j.1478-3231.2012.02791.x.
[29] Midorikawa Y, Takayama T, Higaki T, et al. High platelet count as a poor prognostic factor for liver cancer patients without cirrhosis[J]. Biosci Trends, 2020,14(5):368-375. DOI: 10.5582/bst.2020.03230.
[30] Scheiner B, Kirstein M, Popp S, et al. Association of platelet count and mean platelet volume with overall survival in patients with cirrhosis and unresectable hepatocellular carcinoma[J]. Liver Cancer, 2019,8(3):203-217. DOI: 10.1159/000489833.
[31] Tan RZH, Lockart I, Abdel Shaheed C, et al. Systematic review with meta-analysis: the effects of non-steroidal anti-inflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2021,54(4):356-367. DOI: 10.1111/apt.16515.
[32] Giannini EG, Greco A, Marenco S, et al. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease[J]. Clin Gastroenterol Hepatol, 2010,8(10):899-902. DOI: 10.1016/j.cgh.2010.06.018.
[33] Raparelli V, Basili S, Carnevale R, et al. Low-grade endotoxemia and platelet activation in cirrhosis[J]. Hepatology, 2017, 65(2): 571-581. DOI: 10.1002/hep. 28853.
[34] Zanetto A, Campello E, Bulato C, et al. Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death[J]. J Hepatol, 2022, 77(3): 660-669. DOI: 10.1016/j.jhep.2022.03.009.